Loading…
Shandong state-owned API maker and one of the world's largest producers of caffeine and analgesic bulk drugs.
Shandong state-owned API maker and one of the world's largest producers of caffeine and analgesic bulk drugs.
Makes active drug ingredients in bulk and sells them to drug formulators and, in the case of caffeine, to food and drink makers, so earnings follow the price of each compound rather than brand strength. Finished generic drugs, sold through hospitals and pharmacies in China, are a separate line.
In one line: A Chinese state-owned bulk-analgesic/caffeine API maker.
Moat: narrow (scale). Large-scale bulk API production gives cost advantages in commodity analgesic and caffeine markets.
Headquarters: Zibo, Shandong, China · Employees: 7,240
Size Shandong Xinhua Pharmaceutical (000756.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.09B, the 2147th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.63 on 6 Nov 2026.
Performance Over six months the shares fell 10.3%, against -16.4% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 5.2% over the last twelve months (peer median +5.4%); the operating margin is 3.6% (peer median 14.8%).
Valuation It trades at 18.3× forward earnings against a peer median of 19.9× (8th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.4 points above its cost of capital (7.4% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.05B | CN¥8.73B | CN¥8.47B | CN¥8.01B | CN¥7.44B |
| Revenue growth | — | +3% | +6% | +8% | — |
| Gross profit | CN¥1.82B | CN¥1.45B | CN¥1.90B | CN¥2.21B | CN¥1.88B |
| EBITDA | n/a | CN¥950M | CN¥1.06B | CN¥1.03B | CN¥958M |
| Net income | CN¥229M | CN¥290M | CN¥470M | CN¥497M | CN¥411M |
| Free cash flow | CN¥319M | CN¥428M | CN¥163M | -CN¥51.7M | CN¥521M |
| Capital expenditure | CN¥82.8M | CN¥116M | CN¥212M | CN¥325M | CN¥245M |
| Total debt | CN¥1.76B | CN¥2.03B | CN¥2.14B | CN¥1.87B | CN¥1.89B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shandong Xinhua Pharmaceutical 000756.SZ | $1.09B | -10% | -5% | 4% | 18.3× | 1.5% |
| North China Pharmaceutical 600812.SS | $1.17B | -8% | -21% | 5% | n/a | 1.4% |
| Northeast Pharmaceutical 000597.SZ | $948M | -10% | -6% | 3% | n/a | -6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000756.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.2% | -4.8% | 4th lowest of 21 |
| 6-month return | -10.3% | -16.4% | 8th highest of 21 |
| Distance from 52-week high | -32.5% | -34.9% | 10th highest of 21 |
| Revenue growth (TTM) | -5.2% | +5.4% | 9th lowest of 21 |
| Operating margin | 3.6% | 14.8% | 5th lowest of 20 |
| Forward P/E | 18.3× | 19.9× | 8th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 4.2% | 4th least demanding of 15 |
| Growth delivered (Del g) | +7.9% | +14.4% | 6th lowest of 15 |
| Hurdle (Req g minus delivered) | -6.3 pp | -8.1 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | +1.4 pp | +2.2 pp | 8th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 18.3× | 1.5% | +7.9% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |